Under the terms, biotech firm Roivant will be responsible for funding the development and will retain commercialization rights for RVT-3101, once approved, in the United States and Japan.
https://www.pharmalive.com/wp-content/uploads/2022/05/Pfizer-keeps-COVID-sales-forecast-unchanged-as-pandemic-curbs-ease-Reuters-5-3-22.webp503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-12-01 08:33:052022-12-01 09:22:17Roivant, Pfizer launch unit to develop inflammatory disease drug
